Kohlhas, Viktoria, Hallek, Michael and Nguyen, Phuong-Hien (2020). Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in E mu-TCL1 mice. Blood Adv., 4 (24). S. 6106 - 6117. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537
Full text not available from this repository.Abstract
The treatment of chronic lymphocytic leukemia (CLL) has been improved dramatically by inhibitors targeting B-cell receptor (BCR)-associated kinases. The tyrosine kinase Lyn is a key modulator of BCR signaling and shows increased expression and activity in CLL. To evaluate the functional relevance of Lyn for CLL, we generated a conditional knockin mouse model harboring a gain-of-function mutation of the Lyn gene (LynY508F), which was specifically expressed in the B-cell lineage (Lyn(up-B)). Kinase activity profiling revealed an enhanced responsiveness to BCR stimulation in Lyn(up-B) B cells. When crossing Lyn(up-B) mice with E mu-TCL1 mice (TCL1(tg/wt)), a transgenic mouse model for CLL, the resulting TCL1(tg/wt) Lyn(up-B) mice showed no significant change of hepatomegaly, splenomegaly, bone marrow infiltration, or overall survival when compared with TCL1(tg/wt) mice. Our data also suggested that TCL1 expression has partially masked the effect of the Lyn(up-B) mutation, because the BCR response was only slightly increased in TCL1(tg/wt) Lyn(up-B) compared with TCL1(tg/wt). In contrast, TCL1(tg/wt) Lyn(up-B) were protected at various degrees against spontaneous apoptosis in vitro and upon treatment with kinase inhibitors targeting the BCR. Collectively, and consistent with our previous data in a Lyn-deficient CLL model, these data lend further suggest that an increased activation of Lyn kinase in B cells does not appear to be a major driver of leukemia progression and the level of increased BCR responsiveness induced by Lyn(up-B) is insufficient to induce clear changes to CLL pathogenesis in vivo.
Item Type: | Journal Article | ||||||||||||||||
Creators: |
|
||||||||||||||||
URN: | urn:nbn:de:hbz:38-307557 | ||||||||||||||||
DOI: | 10.1182/bloodadvances.2020002584 | ||||||||||||||||
Journal or Publication Title: | Blood Adv. | ||||||||||||||||
Volume: | 4 | ||||||||||||||||
Number: | 24 | ||||||||||||||||
Page Range: | S. 6106 - 6117 | ||||||||||||||||
Date: | 2020 | ||||||||||||||||
Publisher: | AMER SOC HEMATOLOGY | ||||||||||||||||
Place of Publication: | WASHINGTON | ||||||||||||||||
ISSN: | 2473-9537 | ||||||||||||||||
Language: | English | ||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||
Subjects: | no entry | ||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/30755 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |